Prevalence, Clinical Features and Risk Factors of Cirrhotic Cardiomyopathy Assessed by Two-dimensional Speckle Tracking Imaging

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the prevalence of cirrhotic cardiomyopathy in patients with cirrhosis, and to analyze the correlation between the severity of cirrhosis and cardiac dysfunction. To investigate the risk factors for cirrhotic cardiomyopathy, and raise clinicians' awareness of cirrhotic cardiomyopathy, early assessment and intervention to improve long-term outcomes in patients with cirrhosis.

Detailed Description
-----------------
Liver cirrhosis is the terminal stage of the development of chronic liver disease caused by various reasons, and it is often accompanied by multiple complications. Late cirrhosis is often accompanied by obvious changes in liver and systemic hemodynamics. Patients with liver cirrhosis are in a highly dynamic cycle Status: lower arterial blood pressure, increased heart rate, increased cardiac output, peripheral vascular resistance, which often lead to changes in myocardial structure and function, called cirrhotic cardiomyopathy. Cirrhotic cardiomyopathy (CCM) is defined as cardiac dysfunction in patients with end-stage liver disease in the absence of prior heart disease. The true burden of CCM among patients with ESLD is currently unknown. Prior studies evaluated CCM prevalence and estimated it to be approximately 50%, however, this estimate was based on the old criteria. In 2020, the Cirrhotic Cardiomyopathy Association updated the diagnostic criteria for cirrhotic cardiomyopathy. At present, the true prevalence of cirrhotic cardiomyopathy still needs to be reassessed. In addition, studies on the risk factors for cirrhotic cardiomyopathy are rare. Based on the above research background, carry out this research.

Official Title
-----------------
Prevalence, Clinical Features and Risk Factors of Cirrhotic Cardiomyopathy Assessed by Two-dimensional Speckle Tracking Imaging

Conditions
-----------------
Liver Cirrhosis, Cirrhotic Cardiomyopathy

Intervention / Treatment
-----------------
* Other: Not


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The clear diagnosis of cirrhosis in patients caused by various reasons Exclusion Criteria: History of cardiovascular disease Diabetes High blood pressure Hepatocellular carcinoma (HCC) or other malignant tumors Patients with the chronic obstructive pulmonary disease Thyroid diseases Severe infection in the last 2 weeks History of liver transplantation and/or TIPS surgery Presence of stage 3 or above chronic kidney disease or acute chronic kidney disease Pregnant women Did not sign the informed consent form and refused to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with liver cirrhosis<br>cirrhosis based on either clinical/radiological parameters or liver histology | Other: Not<br>* Not<br>|
| control group<br>Healthy ubjects without known heart disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cirrhotic cardiomyopathy | Different levels of left ventricular diastolic dysfunction in patients with liver cirrhosis | Within 48 hours after hospitalization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cirrhosis; cardiac dysfunction;Cardiac Imaging